÷´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛ(DDS) ½ÃÀå : À¯Çüº°, ¿ëµµº°, ij¸®¾î À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Advanced Drug Delivery Systems Market, By Type, By Application, By Carrier Type, By End User, By Geography
»óǰÄÚµå : 1672650
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 10,128,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ Ã·´Ü DDS(¾à¹°Àü´Þ ½Ã½ºÅÛ) ½ÃÀåÀº 2025³â¿¡´Â 2,694¾ï 8,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 4,027¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â¿¡ CAGR 5.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁØ¿¬µµ 2024 2025³â ½ÃÀå ±Ô¸ð 2,694¾ï 8,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR : 5.90% 2032³â °¡Ä¡ ¿¹Ãø 4,027¾ï 9,000¸¸ ´Þ·¯
µµÇ¥. ÷´Ü DDS ½ÃÀå Á¡À¯À²(%), 2025³â Áö¿ªº°
Advanced Drug Delivery Systems Market-IMG1

÷´Ü DDS´Â ±¹¼Ò Ä¡·á ¹× Áö¼ÓÀû Ä¡·á¸¦ À§ÇØ ¾à¹°À» ü³» ºÎÀ§¿¡ ƯÀÌÀûÀ¸·Î Ÿ±êÆÃÇÒ ¼ö ÀÖ´Â »õ·Î¿î Á¦Çü °³¹ßÀ» °¡´ÉÇÏ°Ô Çß½À´Ï´Ù. ³ª³ëÅ×Å©³î·¯Áö ¹× ±âŸ °øÇÐÀû Á¢±Ù¹ýÀ» ÅëÇØ ¹Ì¼¿, µ§µå¸®¸Ó, ¸®Æ÷Á», °íºÐÀÚ ³ª³ëÀÔÀÚ µî ¾à¹°À» ºÐÇØ·ÎºÎÅÍ º¸È£ÇÏ°í ¹æÃâÀ» Á¦¾îÇÒ ¼ö ÀÖ´Â Áö´ÉÇü Àü´Þü¸¦ ½±°Ô ¸¸µé ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Àü´Þ Ç÷§ÆûÀº ¾à¹°ÀÇ È¿´ÉÀ» ³ôÀÌ°í ¿øÄ¡ ¾Ê´Â ºÎÀÛ¿ëÀ» ÁÙÀÓÀ¸·Î½á ¸¹Àº ¾à¹°ÀÇ Ä¡·á Áö¼ö¸¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû À庮À» ³Ñ¾î Ä¡·á ÆäÀ̷ε带 Á¤È®ÇÏ°Ô Àü´ÞÇÒ ¼ö Àִ ÷´Ü DDS´Â ¾Ï ¹× ±âŸ ½É°¢ÇÑ Áúº´ÀÇ Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

÷´Ü DDS ½ÃÀåÀº Ç¥ÀûÈ­µÈ ¾à¹°Àü´Þ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Çõ½ÅÀûÀÎ Á¦Á¦ °³¹ßÀ» À§ÇÑ Á¦¾à»çµéÀÇ R&D ÅõÀÚ Áõ°¡¿Í ¾Ï°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº °³¹ß ºñ¿ë°ú ±ÔÁ¦ ¹®Á¦°¡ ½Å±Ô ÁøÃâ±â¾÷¿¡°Ô µµÀüÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½ÅÈï ±¹°¡ÀÇ ¹Ì°³¹ß ÀáÀç·ÂÀº ½ÃÀå È®´ëÀÇ ±âȸ°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áö¼ÓÇü ÁÖ»çÁ¦¿Í °°Àº ÷´Ü Àü´Þ ±â¼úÀÇ Àû¿ë ¹üÀ§ È®´ë´Â ÀǾàǰ °³¹ßÀڵ鿡°Ô »õ·Î¿î ±æÀ» ¿­¾îÁÙ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ Ã·´Ü DDS ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ÆÄ¾ÇÇϰí ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ ÁÖ¿ä ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

¼¼°è ÷´Ü DDS ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ °³¿äÀ» ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅ͸¦ ±âÁØÀ¸·Î Á¤¸®ÇÏ¿© ¼ö·ÏÇß½À´Ï´Ù.

ÁÖ¿ä ±â¾÷¿¡´Â Baxter, 3M, Abbott, Datwyler Holding Inc., Evonik, Astrazeneca, Novo Nordisk A/S, Corium Innovations, Inc., PolyActiva, Teleflex Incorporated, Elixir Medical, B. Braun SE, Nemera, Epion Therapeutics, Inc., Terumo Corporation, Flowonix Medical Inc. µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ÷´Ü DDS ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ÷´Ü DDS ½ÃÀå, À¯Çüº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦5Àå ÷´Ü DDS ½ÃÀå, ¿ëµµº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦6Àå ÷´Ü DDS ½ÃÀå, ij¸®¾î À¯Çüº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦7Àå ÷´Ü DDS ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦8Àå ¼¼°èÀÇ Ã·´Ü DDS ½ÃÀå, Áö¿ªº°, 2020-2032³â, ±Ý¾×(10¾ï ´Þ·¯)

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ¾Ö³Î¸®½ºÆ®ÀÇ ±ÇÀå»çÇ×

Á¦11Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Advanced Drug Delivery Systems Market is estimated to be valued at USD 269.48 Bn in 2025 and is expected to reach USD 402.79 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 269.48 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 5.90% 2032 Value Projection: USD 402.79 Bn
Figure. Advanced Drug Delivery Systems Market Share (%), By Region 2025
Advanced Drug Delivery Systems Market - IMG1

Advanced drug delivery systems have enabled the development of novel formulations that can specifically target drugs to areas of the body for localized or sustained treatment. Nanotechnology and other engineering approaches have facilitated the creation of intelligent delivery vehicles like micelles, dendrimers, liposomes, and polymeric nanoparticles that can shield drugs from degradation and control their release. Such delivery platforms help improve the therapeutic index of many drugs by increasing their efficacy and reducing unwanted side effects. With their ability to cross biological barriers and precisely deliver therapeutic payloads, advanced drug delivery systems are revolutionizing the treatment of cancer and other serious diseases.

Market Dynamics:

The advanced drug delivery systems market is driven by the growing demand for targeted and controlled drug delivery. Increasing R&D investments by pharmaceutical companies to develop innovative formulations and the rising prevalence of chronic diseases like cancer are fueling market growth. However, high development costs and regulatory issues pose challenges to new entrants. The untapped potential of emerging economies presents an opportunity for market expansion. Additionally, the growing application scope of advanced delivery technologies like long-acting injectables could open new avenues for drug developers.

Key features of the study:

This report provides in-depth analysis of the global advanced drug delivery systems market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global advanced drug delivery systems market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Baxter, 3M, Abbott, Datwyler Holding Inc., Evonik, Astrazeneca, Novo Nordisk A/S, Corium Innovations, Inc., PolyActiva, Teleflex Incorporated, Elixir Medical, B. Braun SE, Nemera, Epion Therapeutics, Inc., Terumo Corporation, and Flowonix Medical Inc

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global advanced drug delivery systems market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global advanced drug delivery systems market

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, And Trends Analysis

4. Advanced Drug Delivery Systems Market, By Type, 2020-2032, (USD Bn)

5. Advanced Drug Delivery Systems Market, By Application, 2020-2032, (USD Bn)

6. Advanced Drug Delivery Systems Market, By Carrier Type, 2020-2032, (USD Bn)

7. Advanced Drug Delivery Systems Market, By End User, 2020-2032, (USD Bn)

8. Global Advanced Drug Delivery Systems Market, By Region, 2020 - 2032, Value (USD Bn)

9. Competitive Landscape

10. Analyst Recommendations

11. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â